B

Belluscura PLC
LSE:BELL

Watchlist Manager
Belluscura PLC
LSE:BELL
Watchlist
Price: 10.25 GBX 7.89% Market Closed
Market Cap: 17.3m GBX
Have any thoughts about
Belluscura PLC?
Write Note

Belluscura PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Belluscura PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
B
Belluscura PLC
LSE:BELL
Income from Continuing Operations
-$18.5m
CAGR 3-Years
-111%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Income from Continuing Operations
$305m
CAGR 3-Years
-18%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Income from Continuing Operations
$23.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
EKF Diagnostics Holdings PLC
LSE:EKF
Income from Continuing Operations
ÂŁ5.1m
CAGR 3-Years
-32%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Angle PLC
LSE:AGL
Income from Continuing Operations
-ÂŁ18m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Income from Continuing Operations
-ÂŁ22.4m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
No Stocks Found

Belluscura PLC
Glance View

Market Cap
16.3m GBX
Industry
Health Care

Belluscura Plc engages in the provision of medical devices. The Company’s product, the X-PLO2R, is a lightweight portable oxygen concentrator (POC), which is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company focuses on devices and treatments involving oxygen. The X-PLO2R DX is designed to produce approximately six-liters pulse dose oxygen and approximately two-liters of flow oxygen. The firm is focused on developing the medical devices for treating people who are suffering from chronic lung diseases, such as the chronic obstructive pulmonary disease (COPD), respiratory distress caused by coronavirus disease (COVID-19), and other respiratory disorders.

BELL Intrinsic Value
11.52 GBX
Undervaluation 11%
Intrinsic Value
Price
B

See Also

What is Belluscura PLC's Income from Continuing Operations?
Income from Continuing Operations
-18.5m USD

Based on the financial report for Dec 31, 2023, Belluscura PLC's Income from Continuing Operations amounts to -18.5m USD.

What is Belluscura PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-66%

Over the last year, the Income from Continuing Operations growth was -127%. The average annual Income from Continuing Operations growth rates for Belluscura PLC have been -111% over the past three years , -66% over the past five years .

Back to Top